At the same time, alcohol can worsen shared side effects like nausea, vomiting, and dehydration, and it can raise hypoglycemia risk in people with type 2 diabetes
Wegovy and Zepbound are FDA-approved for weight management regardless of diabetes status, but many insurance plans have stricter prior authorization requirements for weight-loss indications than for diabetes
The launch of generic liraglutide (Teva, August 2025) and anticipated oral GLP-1 options (oral Wegovy approved December 2025, orforglipron pending) offer lower-cost alternatives that may simplify pharmacy benefit management
North American region is leading the GLP-1 agonists market.
More evidence about the indirect role of butyrate during insulin secretion has emerged after studies reported its involvement with glucagon-like peptide-1 (GLP-1) secretion from intestinal L-cells (74, 75)
MannKind Corporation MannKind is advancing inhalable peptide therapies and other innovative delivery methods for GLP-1 drugs